Breathing freely over TB patient

Officials at the Centers for Disease Control and Prevention are likely taking a collective sigh of relief. This just in from The Scientist intern Kelly Chi: Today (July 3) representatives from the National Jewish Medical Research Center and the CDC revealed that Andrew Speaker, a patient who sparked international concern after traveling with a highly-resistant form of TB, has multi-drug resistant TB (MDR-TB), not extensively drug-resistant TB (XDR-TB). This means that he can be treated with a

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share
Officials at the Centers for Disease Control and Prevention are likely taking a collective sigh of relief. This just in from The Scientist intern Kelly Chi: Today (July 3) representatives from the National Jewish Medical Research Center and the CDC revealed that Andrew Speaker, a patient who sparked international concern after traveling with a highly-resistant form of TB, has multi-drug resistant TB (MDR-TB), not extensively drug-resistant TB (XDR-TB). This means that he can be treated with a fluoroquinolone or other injectable drugs that would have not been effective against XDR-TB. The first test was conducted by the CDC using a subculture of Speaker's sputum and resulted in an XDR-TB diagnosis. The mycobacteriology laboratory at National Jewish subsequently tested sputum samples taken from Speaker on three separate occasions: April 25 in Atlanta, May 27 in New York, and June 1 in Denver. All tests have revealed MDR-TB, using multiple cultures, multiple ways. However, Mitchell Cohen, director of the Coordinating Center for Infectious Diseases at the CDC, told reporters the public health response would have remained the same even if Speaker had MDR-TB. Robert Cooksey, Speaker's father-in-law who linkurl:works with TB;http://www.the-scientist.com/news/display/53295/ at the CDC, was not involved in any of the tests, Cohen said. The CDC is still determining whether any of the exposed persons have TB.
Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Meet the Author

  • Alison McCook

    This person does not yet have a bio.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
iStock

TaqMan Probe & Assays: Unveil What's Possible Together

Thermo Fisher Logo
Meet Aunty and Tackle Protein Stability Questions in Research and Development

Meet Aunty and Tackle Protein Stability Questions in Research and Development

Unchained Labs
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo